Abstract: Lung cancer is one of the commonest cancers in the world. Among all malignant tumors, lung cancer has the highest fatality rate, while non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancer. As a functional imaging method that reflects the metabolic status of tumor cells at the molecular level, ¹⁸F-fluorodeoxyglucose (FDG) PET/CT has become an important tool for diagnosis, staging and efficacy evaluation of NSCLC. ¹⁸F-FDG PET/CT plays an increasingly important role in the prognosis of the patients with surgically resected NSCLC, because it can detect lesions left out by conventional CT. This paper reviews the application progress of ¹⁸F-FDG PET/CT related metabolic parameters in predicting the prognosis of resectable NSCLC.